Search
p-tert-Butylphenol-formaldehyde resin (low molecular weight)
go.drugbank.com/drugs/DB14190Approvedp-tert-Butylphenol-formaldehyde resin is a widely used adhesive chemical used in a wide variety of commercially available products and a known dermatological sensitizer and allergen [A34290,A34291]. … Sensitivity to p-tert-Butylphenol-formaldehyde resin may be identified with a clinical patch test.
Tetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalTetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. … The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Roxatidine acetate
go.drugbank.com/drugs/DB08806InvestigationalRoxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
N-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
Synonyms: D-GlcNAc, N-Acetyl-D-glucosamineAllogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736ApprovedAllogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital … [L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three.
Pasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.
Thalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. … It has been reintroduced and used for a number of inflammatory disorders and cancers.
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.
Pirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalIts high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. … Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK).